Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The Policy Forum allows health policy makers around the world to discuss challenges
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“For example, inequalities in premature mortality and infant mortality by income and ethnicity in the USA decreased during the period of welfare expansion in the USA ('war on poverty' era 1966 to 1980), but they increased again during the Reagan-Bush period (1980-2002) when welfare services and healthcare coverage were cut.46”
From The COVID-19 pandemic and health inequalities (2020) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global distribution of clinical episodes of Plasmodium falciparum malaria
Snow, R. W., Guerra, C. A., Noor, A. M., Myint, H. Y., & Hay, S. I. (2005) · Nature · doi:10.1038/nature03342 · Cited by 2,741 · cited 3×
“In 2002, Plasmodium falciparum caused at least 0.5 billion uncomplicated clinical attacks of malaria worldwide, particularly in nonimmune young children living in Africa [1].”
BackgroundInfluentialSelf-citationPiaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Reporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement
Piaggio, G., Elbourne, D. R., Altman, D. G., Pocock, S. J., Evans, S. J. W., & CONSORT Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.10.1152 · Cited by 1,153 · cited 2×
“can blur true differences in treatment effects and thus lead to inadvertent conclusion of non-inferiority when in fact the new drug is inferior (type I error) [46,49].”
BackgroundMethodIndicators of Life-Threatening Malaria in African Children
Marsh, K., Forster, D., Waruiru, C., Mwangi, I., Winstanley, M., Marsh, V., Newton, C., Winstanley, P., Warn, P., Peshu, N., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322102 · Cited by 1,097 · cited 1×
“malaria can progress rapidly to life-threatening severe malaria [”
BackgroundSelf-citationTrials to assess equivalence: the importance of rigorous methods: Fig 1
Jones, B., Jarvis, P., Lewis, J. A., & Ebbutt, A. F. (1996) · BMJ · doi:10.1136/bmj.313.7048.36 · Cited by 1,032
Generation of allocation sequences in randomised trials: chance, not choice
Schulz, K. F., & Grimes, D. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07683-3 · Cited by 774
Bhattarai, A., Ali, A. S., Kachur, S. P., Mårtensson, A., Abbas, A. K., Khatib, R., Al-mafazy, A.-W., Ramsan, M., Rotllant, G., Gerstenmaier, J. F., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040309 · Cited by 647 · cited 1×
“], and are thus particularly valuable in situations of low or decreasing transmission rates [”
BackgroundBloland, P. B., Ringwald, P., & Snow, R. W. (2003) · Cited by 630
Self-citationAssessment of the pharmacodynamic properties of antimalarial drugs in vivo
White, N. J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1413 · Cited by 575 · cited 3×
“be estimated by the established “in vivo test” methodology [20].”
BackgroundMethodSelf-citationInnovative lead discovery strategies for tropical diseases
Nwaka, S., & Hudson, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2144 · Cited by 521 · cited 1×
“antimalarial drugs have been described elsewhere and used as guiding principles from early discovery through clinical development [39,40].”
Mutabingwa, T. K. (2005) · Acta Tropica · doi:10.1016/j.actatropica.2005.06.009 · Cited by 352
Price, R. N., Uhlemann, A.-C., van Vugt, M., Brockman, A., Hutagalung, R., Nair, S., Nash, D., Singhasivanon, P., Anderson, T. J. C., Krishna, S., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/503423 · Cited by 317
Self-citationRelapses of Plasmodium vivax Infection Usually Result from Activation of Heterologous Hypnozoites
Imwong, M., Snounou, G., Pukrittayakamee, S., Tanomsing, N., Kim, J. R., Nandy, A., Guthmann, J., Nosten, F., Carlton, J., Looareesuwan, S., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/512241 · Cited by 294
Self-citationAttributable fraction estimates and case definitions for malaria in endemic
Smith, T., Schellenberg, J. A., & Hayes, R. (1994) · Statistics in Medicine · doi:10.1002/sim.4780132206 · Cited by 289
Ratcliff, A., Siswantoro, H., Kenangalem, E., Maristela, R., Wuwung, R., Laihad, F., Ebsworth, E., Anstey, N., Tjitra, E., & Price, R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60160-3 · Cited by 271 · cited 1×
“org 1550 November 2008 | Volume 5 | Issue 11 | e227 a hypothetical example, in times of continued shortage of viable therapeutic options, is it desirable to turn down a new once-daily regimen with a composite efficacy comparable to the recently introduced twice-daily regimen of artemether-lumefantrine, but which may b…”
BackgroundThe past, present and future of childhood malaria mortality in Africa
Snow, R. W., Trape, J.-F., & Marsh, K. (2001) · Trends in Parasitology · doi:10.1016/s1471-4922(01)02031-1 · Cited by 265 · cited 1×
“falciparum in Africa doubled during the 1990s against a rising frequency of resistance to commonly used drugs, such as chloroquine and sulfadoxinepyrimethamine [4].”
BackgroundSelf-citationDesign and analysis of non‐inferiority mortality trials in oncology
Rothmann, M., Li, N., Chen, G., Chi, G. Y. H., Temple, R., & Tsou, H. (2003) · Statistics in Medicine · doi:10.1002/sim.1400 · Cited by 243 · cited 1×
“], the non-inferiority hypothesis of survival estimates can be examined by using a modified confidence interval (CI) approach [”
MethodThe consequences of reducing transmission of Plasmodium falciparum in Africa
SNOW, R., & MARSH, K. (2002) · Advances in Parasitology · doi:10.1016/s0065-308x(02)52013-3 · Cited by 223 · cited 1×
“falciparum malaria can progress rapidly to life-threatening severe malaria [2,3], mortality from P.”
BackgroundSelf-citationPiola, P., Fogg, C., Bajunirwe, F., Biraro, S., Grandesso, F., Ruzagira, E., Babigumira, J., Kigozi, I., Kiguli, J., Kyomuhendo, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66416-1 · Cited by 211
DJIMDÉ, A. A., DOUMBO, O. K., TRAORE, O., GUINDO, A. B., KAYENTAO, K., DIOURTE, Y., NIARE-DOUMBO, S., COULIBALY, D., KONE, A. K., CISSOKO, Y., et al. (2003) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2003.69.558 · Cited by 182
The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya
Amin, A. A., Zurovac, D., Kangwana, B. B., Greenfield, J., Otieno, D. N., Akhwale, W. S., & Snow, R. W. (2007) · Malaria Journal · doi:10.1186/1475-2875-6-72 · Cited by 174
Self-citationKamya, M. R., Yeka, A., Bukirwa, H., Lugemwa, M., Rwakimari, J. B., Staedke, S. G., Talisuna, A. O., Greenhouse, B., Nosten, F., Rosenthal, P. J., et al. (2007) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0020020 · Cited by 169 · cited 1×
“provides additional public health benefits, especially in high-transmission areas where re-infection rates can exceed 50% in less than six weeks [”
BackgroundAntimalarial dosing regimens and drug resistance
Barnes, K. I., Watkins, W. M., & White, N. J. (2008) · Trends in Parasitology · doi:10.1016/j.pt.2007.11.008 · Cited by 161 · cited 1×
“Pharmacogenetic differences have not been shown to play a major role in the variation in therapeutic response (although there are relatively few studies), but pharmacokinetic differences related to age and pregnancy have been large, and clinically important for several antimalarials [19].”
BackgroundSelf-citationStaedke, S. G., Kamya, M. R., Dorsey, G., Gasasira, A. F., Ndeezi, G., Charlebois, E. D., & Rosenthal, P. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05557-x · Cited by 137 · cited 1×
“Clinical endpoints, which measure the reduction of these clinical events, provide important public health–relevant information above parasitologically defined endpoints [15,36,37].”
BackgroundGenotyping of Plasmodium falciparum infections by PCR: a comparative multicentre study
Färnert, A., Arez, A. P., Babiker, H. A., Beck, H. P., Benito, A., Björkman, A., Bruce, M. C., Conway, D. J., Day, K. P., Henning, L., et al. (2001) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(01)90175-0 · Cited by 135 · cited 1×
“rates or (2) remain indeterminate (unclassifiable) [29,30], especially in high-transmission areas when”
BackgroundEpstein, J. E., Rao, S., Williams, F., Freilich, D., Luke, T., Sedegah, M., Vega, P. D. L., Sacci, J., Richie, T. L., & Hoffman, S. L. (2007) · The Journal of Infectious Diseases · doi:10.1086/518510 · Cited by 124 · cited 4×
“As many drugs have no effects on pre-erythrocytic (liver stage) development, new blood stage infections may become patent as early as one week after blood concentrations of the antimalarial drug fall below the minimum inhibitory concentration (MIC) [24].”
BackgroundInfluentialIn Vivo Assessment of Drug Efficacy against Plasmodium falciparum Malaria: Duration of Follow-Up
Stepniewska, K., Taylor, W. R. J., Mayxay, M., Price, R. N., Smithuis, F., Guthmann, J., Barnes, K. I., Myint, H. Y., Adjuik, M., Olliaro, P., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4271-4280.2004 · Cited by 120
Self-citationPoints to consider on switching between superiority and non-inferiority.
(2001) · PubMed Central · doi:10.1046/j.0306-5251.2001.01397-3.x · Cited by 115
Zongo, I., Dorsey, G., Rouamba, N., Tinto, H., Dokomajilar, C., Guiguemdé, R. T., Rosenthal, P. J., & Ouédraogo, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60236-0 · Cited by 114
Staedke, S. G., Mpimbaza, A., Kamya, M. R., Nzarubara, B., Dorsey, G., & Rosenthal, P. J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17478-3 · Cited by 113 · cited 1×
“transmission areas where re-infection rates can exceed 50% in less than six weeks [10,11].”
BackgroundPrice, R. N., Hasugian, A. R., Ratcliff, A., Siswantoro, H., Purba, H. L. E., Kenangalem, E., Lindegardh, N., Penttinen, P., Laihad, F., Ebsworth, E. P., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00486-07 · Cited by 97 · cited 1×
““Indeterminate” results prompt a careful analysis of trial-related inadequacies, especially in case of trials that demonstratethe non-inferiority of the new treatment but fall short of the over 90p criterion. There is also need for caution when applying the over 90p criterion to studies from high-transmission areas be…”
BackgroundEstimating the needs for artesunate-based combination therapy for malaria case-management in Africa
Snow, R. W., Eckert, E., & Teklehaimanot, A. (2003) · Trends in Parasitology · doi:10.1016/s1471-4922(03)00168-5 · Cited by 86 · cited 1×
“In recent years, the deployment of highly efficacious oral three-day regimens of artemisinin-based combination therapies (ACTs) with parasitological cure rates of 95% or greater in more than 40 endemic countries has radically changed antimalarial treatment [”
BackgroundSelf-citationHow antimalarial drug resistance affects post-treatment prophylaxis
White, N. J. (2008) · Malaria Journal · doi:10.1186/1475-2875-7-9 · Cited by 82 · cited 3×
“The superiority of the post-treatment prophylactic efficacy of a new drug with comparatively higher anti-liver stage activity or prolonged plasma half-life can be best examined in areas with high re-infection rates because of the postulated differential impact on re-infection and/or secondary malaria rates [33].”
BackgroundInfluentialSelf-citationPitfalls in Estimating Piperaquine Elimination
Tarning, J., Lindegårdh, N., Annerberg, A., Singtoroj, T., Day, N. P. J., Ashton, M., & White, N. J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5127-5128.2005 · Cited by 79 · cited 1×
“org 1550 November 2008 | Volume 5 | Issue 11 | e227 a hypothetical example, in times of continued shortage of viable therapeutic options, is it desirable to turn down a new once-daily regimen with a composite efficacy comparable to the recently introduced twice-daily regimen of artemether-lumefantrine, but which may b…”
BackgroundSelf-citationStepniewska, K., & White, N. J. (2006) · Malaria Journal · doi:10.1186/1475-2875-5-127 · Cited by 78 · cited 9×
“The preferred method for comparing antimalarial drug efficacy, however, is survival analysis [9].”
BackgroundMethodInfluentialSelf-citationA systematic overview of published antimalarial drug trials
Myint, H. Y., Tipmanee, P., Nosten, F., Day, N. P. J., Pukrittayakamee, S., Looareesuwan, S., & White, N. J. (2004) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(03)00014-2 · Cited by 76 · cited 1×
“[9,45], but there is a dramatic increase in the sample sizes required to demonstrate superiority of a potential future replacement for a drug with currently very high parasitological”
BackgroundSelf-citationGreenhouse, B., Dokomajilar, C., Hubbard, A., Rosenthal, P. J., & Dorsey, G. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00159-07 · Cited by 72 · cited 1×
“Based on the above considerations, whilst it is clear that, in areas of very high transmission, multiplicity of infection confers a significant and irreducible error in genotyping [38], parasite “strain typing” with the highest possible resolution power is required for separating curative and preventive effects in reg…”
BackgroundMedicines for Malaria Venture: sustaining antimalarial drug development
Bathurst, I., & Hentschel, C. (2006) · Trends in Parasitology · doi:10.1016/j.pt.2006.05.011 · Cited by 72
World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs
Price, R. N., Dorsey, G., Ashley, E. A., Barnes, K. I., Baird, J. K., d'Alessandro, U., Guerin, P. J., Laufer, M. K., Naidoo, I., Nosten, F., et al. (2007) · Malaria Journal · doi:10.1186/1475-2875-6-119 · Cited by 69 · cited 5×
“This dependence of clinical risks on the prevalence of acquired immunity in the study population or age group [18,34] (on top of large”
BackgroundMethodInfluentialSelf-citationMonitoring and Deterring Drug-Resistant Malaria in the Era of Combination Therapy
Laufer, M. K., DJIMDÉ, A. A., & Plowe, C. V. (2007) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2007.77.160 · Cited by 69 · cited 3×
“In the era of highly efficacious ACTs there is considerable debate among experts on what, exactly, constitutes the most relevant property of a new antimalarial drug [9,15].”
BackgroundUhlemann, A., McGready, R. M., Ashley, E. A., Brockman, A., Singhasivanon, P., Krishna, S., White, N. J., Nosten, F. H., & Price, R. N. (2006) · The Journal of Infectious Diseases · doi:10.1086/509809 · Cited by 55 · cited 2×
“spread of resistance [9,12], and are thus particularly valuable in situations of low or decreasing transmission rates [13] where the likelihood of re-infection during the relatively short post-treatment prophylactic”
BackgroundSelf-citationSlater, M., KIGGUNDU, M., Dokomajilar, C., Kamya, M. R., Bakyaita, N. N., Talisuna, A. O., Rosenthal, P. J., & Dorsey, G. (2005) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2005.73.256 · Cited by 44
Collins, W. J., Greenhouse, B., Rosenthal, P. J., & Dorsey, G. (2006) · Malaria Journal · doi:10.1186/1475-2875-5-122 · Cited by 40 · cited 1×
“rates or (2) remain indeterminate (unclassifiable) [29,30], especially in high-transmission areas when”
BackgroundComplexity ofPlasmodium falciparumInfections and Antimalarial Drug Efficacy at 7 Sites in Uganda
Lee, S. A., Yeka, A., Nsobya, S. L., Dokomajilar, C., Rosenthal, P. J., Talisuna, A. O., & Dorsey, G. (2006) · The Journal of Infectious Diseases · doi:10.1086/501473 · Cited by 39
Borrmann, S., Matsiegui, P., Missinou, M. A., & Kremsner, P. G. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00755-07 · Cited by 23
Self-citationCan estimates of antimalarial efficacy from field studies be improved?
Gatton, M. L., & Cheng, Q. (2008) · Trends in Parasitology · doi:10.1016/j.pt.2007.11.003 · Cited by 20
Guthmann, J., Pinoges, L., Checchi, F., Cousens, S. N., Balkan, S., Herp, M. V., Legros, D., & Olliaro, P. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01618-05 · Cited by 20
Risk associated with asymptomatic parasitaemia occurring post‐antimalarial treatment
Olliaro, P., Pinoges, L., Checchi, F., Vaillant, M., & Guthmann, J. (2008) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2007.01977.x · Cited by 19
Machekano, R., Dorsey, G., & Hubbard, A. (2007) · Statistical Methods in Medical Research · doi:10.1177/0962280207078202 · Cited by 6
Research works printed but not linked: 46
- Snow, 2005, Nature, 434, 214
- Marsh, 1995, N Engl J Med, 332, 1399
- Snow, 2002, Adv Parasitol, 52, 235
- Snow, 2001, Trends Parasitol, 17, 593
- Snow, 2003, Trends Parasitol, 19, 363
- Mutabingwa, 2005, Acta Trop, 95, 305
- Bathurst, 2006, Trends Parasitol, 22, 301
- Amin, 2007, Malar J, 6, 72
- Stepniewska, 2006, Malar J, 5, 127
- Kamya, 2007, PLoS Clin Trials, 2, e20
- Staedke, 2004, Lancet, 364, 1950
- Uhlemann, 2007, J Infect Dis, 195, 134
- Bhattarai, 2007, PLoS Med, 4, e309
- Laufer, 2007, Am J Trop Med Hyg, 77, 160
- Borrmann, 2008, Antimicrob Agents Chemother, 52, 1799
- Piola, 2005, Lancet, 365, 1467
- Price, 2007, Malar J, 6, 119
- Barnes, 2008, Trends Parasitol, 24, 127
- White, 1997, Antimicrob Agents Chemother, 41, 1413
- Djimde, 2003, Am J Trop Med Hyg, 69, 558
- Stepniewska, 2004, Antimicrob Agents Chemother, 48, 4271
- Price, 2006, Clin Infect Dis, 42, 1570
- Epstein, 2007, J Infect Dis, 196, 145
- Guthmann, 2006, Antimicrob Agents Chemother, 50, 3734
- Lee, 2006, J Infect Dis, 193, 1160
- Slater, 2005, Am J Trop Med Hyg, 73, 256
- Gatton, 2008, Trends Parasitol, 24, 68
- Collins, 2006, Malar J, 5, 122
- Farnert, 2001, Trans R Soc Trop Med Hyg, 95, 225
- Imwong, 2007, J Infect Dis, 195, 927
- White, 2008, Malar J, 7, 9
- Olliaro, 2008, Trop Med Int Health, 13, 83
- Smith, 1994, Stat Med, 13, 2345
- Staedke, 2001, Lancet, 358, 368
- Zongo, 2007, Lancet, 369, 491
- Greenhouse, 2007, Antimicrob Agents Chemother, 51, 3096
- Nwaka, 2006, Nat Rev Drug Discov, 5, 941
- Ratcliff, 2007, Lancet, 369, 757
- Tarning, 2005, Antimicrob Agents Chemother, 49, 5127
- Schulz, 2002, Lancet, 359, 515
- Myint, 2004, Trans R Soc Trop Med Hyg, 98, 73
- Jones, 1996, BMJ, 313, 36
- Piaggio, 2006, JAMA, 295, 1152
- Machekano, 2008, Stat Methods Med Res, 17, 191
- Rothmann, 2003, Stat Med, 22, 239
- Price, 2007, Antimicrob Agents Chemother, 51, 4090
Cited by
The COVID-19 pandemic and health inequalities
Bambra, C., Riordan, R., Ford, J., & Matthews, F. (2020) · Journal of Epidemiology and Community Health · doi:10.1136/jech-2020-214401 · Cited by 2,118
Beckfield, J., & Krieger, N. (2009) · Epidemiologic Reviews · doi:10.1093/epirev/mxp002 · Cited by 384
Bambra, C. (2011) · Journal of Epidemiology and Community Health · doi:10.1136/jech.2011.136333 · Cited by 284
Borrmann, S., Sasi, P. G., Mwai, L., Bashraheil, M. M., Abdallah, A. M., Muriithi, S., Frühauf, H., Schaub, B., Pfeil, J., Peshu, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026005 · Cited by 134
“Reinfection rates by day 84, which could have confounded PCRbased classification of recrudescent primary infections [22], were high but did not change over time (P.”
BackgroundSelf-citationThe perils of PCR: can we accurately ‘correct’ antimalarial trials?
Juliano, J. J., Gadalla, N. B., Sutherland, C. J., & Meshnick, S. R. (2010) · Trends in Parasitology · doi:10.1016/j.pt.2009.12.007 · Cited by 52
“For antimalarial trials, these could include [3]:”
Background
Metadata
- Authors
- Borrmann, S., Peto, T., Snow, R. W., Gutteridge, W., & White, N. J.
- Affiliations
- Kenya Medical Research Institute (KE)
- Heidelberg University (DE)
- Corresponding author
- Borrmann, Steffen
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-11-18
- Volume
- 5
- Issue
- 11
- Pages
- e227
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2586344
- OpenAlex
- W2026681785
- Cited by
- 15
- References
- 49
- Citations by year
- 2022: 2 · 2021: 1 · 2020: 1 · 2019: 1 · 2017: 1 · 2014: 1 · 2012: 1
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Funders
- Wellcome Trust (079080)
- Deutsche Forschungsgemeinschaft (SFB 544, A7, SFB544)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
- Keywords
- antimalarial drugs, trial design, uncomplicated malaria, Plasmodium falciparum, malaria treatment efficacy, health policy
- MeSH terms
- Animals, Antimalarials, Drug Therapy, Combination, Humans, Plasmodium falciparum, Survival Analysis, Malaria, Falciparum, Treatment Outcome, Clinical Trials, Phase III as Topic, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.